Disease · HP_0001324
Muscle weakness
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Muscle weakness. Diseases, record HP_0001324. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001324
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Muscle weakness
- Open Targets ID
- HP_0001324
- Other names
- Muscular weakness
- Highest stage of its drugs
- Approval, for 4 of its 17 drugs, from DailyMed and PMDA
Source Open Targets
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ACENEURAMIC ACID | CHEMBL2105945 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| AMIFAMPRIDINE PHOSPHATE | CHEMBL3301611 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| LEVOCARNITINE | CHEMBL1149 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| MAGNESIUM CHLORIDE | CHEMBL3185229 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMINO ACIDS | CHEMBL1201498 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| GSK2881078 | CHEMBL3545174 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| LORCASERIN | CHEMBL360328 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CALCIUM CARBONATE | CHEMBL1200539 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets45
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AR | Androgen receptor | 2 | Androgen Receptor agonist; Androgen Receptor modulator | Phase 2/3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| KCNA1 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3736 | Drugs and targets |
| KCNA10 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3744 | Drugs and targets |
| KCNA2 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3737 | Drugs and targets |
| KCNA3 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3738 | Drugs and targets |
| KCNA4 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3739 | Drugs and targets |
| KCNA5 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3741 | Drugs and targets |
| KCNA6 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3742 | Drugs and targets |
| KCNA7 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3743 | Drugs and targets |
| KCNB1 | Voltage-gated potassium channel | 2 | Voltage-gated potassium channel blocker | Approval | https://conductscience.org/library/genes/3745 | Drugs and targets |
1 to 10 of 45
See all 45 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03359473 | Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | 97 | 2020-07-15 | Cachexia | GSK2881078 | Its record names the disease | ClinicalTrials.gov |
| NCT04141670 | S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) | Phase 1 | 7 | 2024-04-19 | RYR-1 Myopathy | SURLORIAN | Its record names the disease | ClinicalTrials.gov |
| NCT02523690 | Evaluating Muscle Weakness Improvement With Lorcaserin in ICU | Phase 1/2 | 5 | 2020-01-13 | Muscle Weakness, Sepsis | LORCASERIN | Its record names the disease | ClinicalTrials.gov |
| NCT01837498 | Reversal of Neuromuscular Blockade in Thoracic Surgical Patients | 200 | Residual Neuromuscular Blockade | NEOSTIGMINE, SUGAMMADEX | Its record names the disease | ClinicalTrials.gov | ||
| NCT02873559 | Effect of PROGRESSive Training and Teststerone in Older Frail Men | Phase 2/3 | 192 | Muscle Weakness | TESTOSTERONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03021902 | Nutrition and Exercise in Critical Illness | Phase 2 | 115 | Acute Respiratory Failure | AMINO ACIDS | Its record names the disease | ClinicalTrials.gov | |
| NCT00933868 | Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke | Phase 2/3 | 81 | Stroke | MAGNESIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06984068 | Effect of Vitamin D Supplementation on the Rehabilitation of Patients After Rotator Cuff Tear Repair | Not applicable | 44 | Rotator Cuff Tear | ERGOCALCIFEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT00682214 | Cholecalciferol Supplementation, Muscle Strength | Phase 1 | 40 | Vitamin D Deficiency | CALCIUM CARBONATE, CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT00535158 | Vitamin D 2 to Dialysis Patients | 18 | Kidney Disease, Muscle Weakness, Pain, Fractures, Bone | ERGOCALCIFEROL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Low Dose Group vs High Dose Group: deaths from any cause | 0 of 3 | 0 of 4 | 7 | NCT04141670 | Trial comparisons |
| Low Dose Group vs High Dose Group: serious adverse events | 0 of 3 | 0 of 4 | 7 | NCT04141670 | Trial comparisons |
| Intervention vs Control: deaths from any cause | 0 of 3 | 0 of 2 | 5 | NCT02523690 | Trial comparisons |
| Intervention vs Control: serious adverse events | 0 of 3 | 0 of 2 | 5 | NCT02523690 | Trial comparisons |
Papers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001324
GET https://conductscience.org/api/diseases/v1/HP_0001324/targets?page=2